Anemia as a predictive factor for brain metastases: A propensity score matched retrospective cohort study.

A Akshay Ratnani (1Jefferson Einstein Philadelphia Hospital, Philadelphia, United States) C Colton Jones (2University of Texas-San Antonio, Mays Cancer Center, Hematology/oncology, San Antonio, United States) T Thitiphan Srikulmontri (Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States) P Phuuwadith Wattanachayakul (University of California Irvine School of Medicine, Orange, California, United States) E Elvis Obomanu S Sarah Eidbo (1Jefferson Einstein Philadelphia Hospital, Internal Medicine, Philadelphia, United States) Y Yajur Arya (1Mayo Clinic, Hematology & Oncology, Jacksonville, United States) A Arshi Syal (1Mayo Clinic, Hematology & Oncology, Jacksonville, United States) A Andrew Geller (1Jefferson Einstein Philadelphia Hospital, Internal Medicine, Philadelphia, United States) T Tara John (Jefferson Einstein Philadelphia Hospital, Philadelphia, PA) F Fnu Deepali (Jefferson Einstein Philadelphia Hospital, Philadelphia, PA) G Gabor Varadi (3Jefferson Einstein Philadelphia Hospital, Hematology/oncology, Philadelphia, United States)

Abstract

e14014 Background: Renal cell carcinoma, lung carcinoma, breast carcinoma, and melanoma are cancers that commonly metastasize to the brain. Currently, it is unknown what makes a person more likely to develop brain metastases. Anemia might be linked with tumor hypoxia, which induces angiogenesis and increases tumor aggressiveness. However, it is unclear how anemia might affect the risk of brain metastases in these patients. Methods: We utilized the 2024 TriNetX database in conducting this retrospective cohort study. We identified patients with anemia since 2010 using appropriate ICD-10 diagnostic codes. We stratified patients into two cohorts based on the degree of their hemoglobin level: cohort 1 consisted of patients with a hemoglobin of 7-9.9 gm/dL, while cohort 2 consisted of patients with a hemoglobin of 10-13 gm/dL. Kaplan-Meier Analysis with log-rank test was used to calculate hazard ratios (HRs) for brain metastases and other secondary outcomes. A p-value < 0.05 was considered statistically significant. Results: Each cohort consisted of 57,134 patients after propensity score matching with similar baseline characteristics. Average age at the time of index was 66 years in both groups, and 47% of each cohort was female. In cohort 1, the ethnicity distribution was 59% White, 6% Hispanic, and 18% African American. In cohort 2, the ethnicity distribution was 60% White, 6% Hispanic, and 18% African American. Upon analysis, our study found that, within the last 25 years, patients with a lower hemoglobin level had significantly higher risk of brain metastases (HR 1.62, 95% CI: 1.55–1.69, p < 0.0001). These same patients also had a higher risk for stroke (HR 1.44, 95% CI: 1.37–1.51, p < 0.0001), seizure (HR 1.53, 95% CI: 1.45–1.61, p < 0.0001), intracerebral hemorrhage (HR 1.61, 95% CI: 1.45–1.78, p < 0.0001), hospitalizations (HR 2.24, 95% CI: 2.20–2.28, p < 0.0001), and all-cause mortality (HR 2.92, 95% CI: 2.86–2.98, p < 0.0001). Conclusions: Our study found that patients with lower hemoglobin levels have an increased risk of brain metastases, stroke, seizure, intracerebral hemorrhage, hospitalizations, and all-cause mortality. Further longitudinal studies are needed to explore the relationship between anemia and brain metastases.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (12)

A

Akshay Ratnani

1Jefferson Einstein Philadelphia Hospital, Philadelphia, United States

C

Colton Jones

2University of Texas-San Antonio, Mays Cancer Center, Hematology/oncology, San Antonio, United States

T

Thitiphan Srikulmontri

Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States

P

Phuuwadith Wattanachayakul

University of California Irvine School of Medicine, Orange, California, United States

E

Elvis Obomanu

S

Sarah Eidbo

1Jefferson Einstein Philadelphia Hospital, Internal Medicine, Philadelphia, United States

Y

Yajur Arya

1Mayo Clinic, Hematology & Oncology, Jacksonville, United States

A

Arshi Syal

1Mayo Clinic, Hematology & Oncology, Jacksonville, United States

A

Andrew Geller

1Jefferson Einstein Philadelphia Hospital, Internal Medicine, Philadelphia, United States

T

Tara John

Jefferson Einstein Philadelphia Hospital, Philadelphia, PA

F

Fnu Deepali

Jefferson Einstein Philadelphia Hospital, Philadelphia, PA

G

Gabor Varadi

3Jefferson Einstein Philadelphia Hospital, Hematology/oncology, Philadelphia, United States